Mizuho Initiates Coverage on Pulse Biosciences (NASDAQ:PLSE)

Stock analysts at Mizuho assumed coverage on shares of Pulse Biosciences (NASDAQ:PLSE) in a research report issued to clients and investors on Friday, MarketBeat.com reports. The brokerage set an “outperform” rating and a $25.00 price target on the stock. Mizuho’s target price would suggest a potential upside of 80.77% from the stock’s current price.

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Pulse Biosciences in a research report on Thursday, January 22nd. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Pulse Biosciences currently has a consensus rating of “Hold” and an average price target of $23.50.

Pulse Biosciences Stock Performance

Shares of NASDAQ PLSE opened at $13.83 on Friday. The stock has a market cap of $937.26 million, a price-to-earnings ratio of -12.24 and a beta of 1.69. Pulse Biosciences has a fifty-two week low of $12.56 and a fifty-two week high of $25.00. The firm’s 50-day simple moving average is $14.10 and its 200 day simple moving average is $15.46.

Pulse Biosciences (NASDAQ:PLSE) last issued its quarterly earnings data on Wednesday, November 5th. The company reported ($0.29) earnings per share for the quarter, beating the consensus estimate of ($0.31) by $0.02.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. AlphaQuest LLC boosted its stake in Pulse Biosciences by 184.5% in the second quarter. AlphaQuest LLC now owns 8,864 shares of the company’s stock worth $134,000 after buying an additional 5,748 shares in the last quarter. Inspire Investing LLC lifted its holdings in shares of Pulse Biosciences by 19.7% in the 2nd quarter. Inspire Investing LLC now owns 25,891 shares of the company’s stock worth $391,000 after acquiring an additional 4,267 shares during the last quarter. Westside Investment Management Inc. lifted its holdings in shares of Pulse Biosciences by 10.5% in the 2nd quarter. Westside Investment Management Inc. now owns 64,290 shares of the company’s stock worth $970,000 after acquiring an additional 6,135 shares during the last quarter. Bender Robert & Associates purchased a new stake in shares of Pulse Biosciences in the 2nd quarter valued at $175,000. Finally, Brooklyn Investment Group grew its holdings in shares of Pulse Biosciences by 5,313.1% during the 3rd quarter. Brooklyn Investment Group now owns 30,259 shares of the company’s stock valued at $536,000 after purchasing an additional 29,700 shares during the last quarter. 76.95% of the stock is currently owned by institutional investors.

About Pulse Biosciences

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.